Recombinant technology eliminates the possibility of adaptation or mutation by replicating only the haemagglutinin (HA) antigen direct from a genetic sequence. The resulting antigens are an exact genetic match to the target strain HA antigen.3,6
Supemtek contains 3x more HA antigen (45 mcg versus 15 mcg) per strain, compared with cell-
and egg-based standard-dose quadrivalent influenza vaccines.3
Supemtek demonstrated 30% greater relative efficacy (1% absolute efficacy) versus standard-dose egg-based quadrivalent inactivated influenza vaccine (QIVe), in preventing confirmed cases of influenza-like illness in adults ≥50 years of age, with respective influenza attack rates of
2.2% and 3.2 %.†3
Supemtek demonstrated a comparable safety profile to standard-dose egg-based QIVe.3,7
Randomised controlled trials support the efficacy and safety of Supemtek for active immunisation for the prevention of influenza disease in adults ≥18 years of age.3,7
Results from a European Centre for Disease Prevention and Control (ECDC) systematic literature review to assess the efficacy, effectiveness and safety of enhanced influenza vaccines (versus standard-dose or placebo) for the prevention of laboratory-confirmed influenza in adults ≥18 years of age suggested that Supemtek may offer ”better protection than no vaccination, or standard influenza vaccines.”(QIVe)8